Clinical trials in Bielefeld – page 2

146 clinical trials in Bielefeld, Germany across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in GermanyKlinischeStudien.de

Bielefeld at a glance

146

clinical trials

Research sites1

Quick filters

146 trials in Bielefeld

Open in trial search

Asthma

Recruiting

Efficacy and safety of indacaterol acetate (combined with glycopyrronium bromide and mometasone furoate) versus salmeterol/fluticasone in adolescents with asthma

Registered drug

Efficacy and safety of indacaterol acetate (combined with glycopyrronium bromide and mometasone furoate) versus salmeterol/fluticasone in adolescents with asthma

Registered drug

Germany

Participants:0–17 years
Substances:Indacaterol Acetate
Sponsor:Novartis Pharma AG

Contact Research Centre

Acute kidney injury+2

Recruiting

Effect of sodium hydrogen carbonate on kidney health in critically ill patients with metabolic acidosis and acute kidney injury

Registered drugNo placebo

Effect of sodium hydrogen carbonate on kidney health in critically ill patients with metabolic acidosis and acute kidney injury

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Malic acid
Sponsor:Universitaet Muenster

Contact Research Centre

Breast cancer+4

Recruiting

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo

Study of elacestrant and ribociclib compared to standard treatment for patients with high-risk ER+/HER2- early breast cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Elacestrant
Sponsor:WSG Women's Cancer Study Group GmbH

Contact Research Centre

Non-small cell lung cancer

Recruiting

A study comparing the effectiveness and safety of datopotamab deruxtecan and docetaxel in adults with advanced or metastatic non-squamous non-small cell lung cancer

Registered drugNo placebo

A study comparing the effectiveness and safety of datopotamab deruxtecan and docetaxel in adults with advanced or metastatic non-squamous non-small cell lung cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Docetaxel
Sponsor:AstraZeneca AB

Contact Research Centre

Neuroendocrine carcinoma of the skin

Recruiting

A Study of Cemiplimab Given Before Surgery in Patients with Early Stage Merkel Cell Carcinoma of the Skin

Registered drug

A Study of Cemiplimab Given Before Surgery in Patients with Early Stage Merkel Cell Carcinoma of the Skin

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Cemiplimab
Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Contact Research Centre

Hodgkin's disease

Recruiting

A Study of Pembrolizumab and Radiotherapy for Patients with Early-Stage Favorable Classic Hodgkin Lymphoma

Registered drugNo placebo

A Study of Pembrolizumab and Radiotherapy for Patients with Early-Stage Favorable Classic Hodgkin Lymphoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Pembrolizumab
Sponsor:University Of Cologne

Contact Research Centre

Oesophageal adenocarcinoma

Recruiting

Study of zanidatamab with drug combination for patients with HER2 and PD-L1 positive advanced gastroesophageal cancer

Registered drugNo placebo

Study of zanidatamab with drug combination for patients with HER2 and PD-L1 positive advanced gastroesophageal cancer

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Fluorouracil
Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Contact Research Centre

Diabetes mellitus

Recruiting

A Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes

Investigational

A Study of Teplizumab Compared to Placebo for Blood Sugar Control in Children and Young Adults Aged 1 to 25 Years with Newly Diagnosed Type 1 Diabetes

Investigational

Germany

Participants:0–17 years · 18–64 years
Substances:Teplizumab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Ischaemic stroke

Recruiting

A study testing tenecteplase given directly into the artery after blood clot removal in patients with acute ischemic stroke in the front part of the brain

Registered drug

A study testing tenecteplase given directly into the artery after blood clot removal in patients with acute ischemic stroke in the front part of the brain

Registered drug

Germany

Participants:18–64 years · 65+ years
Substances:Tenecteplase
Sponsor:Universitaetsklinikum Heidelberg AöR

Contact Research Centre

Generalised tonic-clonic seizure+1

Recruiting

Study of PRAX-628 to evaluate safety and effectiveness in adults with epilepsy who have focal seizures or generalized tonic-clonic seizures

InvestigationalNo placebo

Study of PRAX-628 to evaluate safety and effectiveness in adults with epilepsy who have focal seizures or generalized tonic-clonic seizures

InvestigationalNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:PRAX-628
Sponsor:Praxis Precision Medicines Inc.

Contact Research Centre

Diffuse large B-cell lymphoma+2

Recruiting

Study of loncastuximab tesirine and epcoritamab combination treatment for patients with relapsed or refractory diffuse large B-cell lymphoma

Registered drugNo placebo

Study of loncastuximab tesirine and epcoritamab combination treatment for patients with relapsed or refractory diffuse large B-cell lymphoma

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Epcoritamab
Sponsor:Universitaet Muenster

Contact Research Centre

Atrial fibrillation+1

Recruiting

Study of drug combination therapy for prevention of recurrent stroke in patients with acute ischemic stroke and atrial fibrillation

Registered drugNo placebo

Study of drug combination therapy for prevention of recurrent stroke in patients with acute ischemic stroke and atrial fibrillation

Registered drugNo placebo

Germany

Participants:18–64 years · 65+ years
Substances:Flecainide Acetate
Sponsor:University Medical Center Hamburg-Eppendorf

Contact Research Centre

Other cities in Germany

The busiest research cities in the country

All 518 cities in Germany

Clinical research in Bielefeld

What the registry says about research in the country

01 Oncology Research

Extensive studies focusing on breast cancer treatments, including innovative therapies for HR-positive and HER2-negative variants. Research extends to gastric cancer and advanced ovarian cancer treatments.

Early-stage breast cancer therapies
Gastroesophageal junction cancer treatments
Ovarian cancer maintenance therapy

Novel combinations of targeted therapies and immunotherapies are being evaluated for improved patient outcomes.

02 Neurological Disorders

Comprehensive research into epilepsy and seizure disorders, with particular focus on both focal onset and generalized seizures. Studies include investigations of new treatments for Dravet Syndrome.

Seizure frequency reduction therapies
Extended-release anticonvulsant medications
Migraine prevention treatments

Emphasis on developing long-term treatment solutions for various seizure types.

03 Dermatology Studies

Investigation of treatments for plaque psoriasis and preventive measures for atopic dermatitis in high-risk populations. Focus on both adult and pediatric patients.

Moderate to severe psoriasis treatments
Preventive dermatological care
Long-term safety evaluations

Studies aim to develop effective management strategies for chronic skin conditions.

Back to Germany All countries